OVID

Ovid Therapeutics Inc. [OVID] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

OVID Stock Summary

Top OVID Correlated Resources

OVID


Top 10 Correlated ETFs

OVID


Top 10 Correlated Stocks

OVID


In the News

10:00 08 Dec 2022 OVID

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant seizures will be presented at the 2022 American Epilepsy Society (AES) Annual Meeting, taking place December 2-6 in Nashville, Tennessee.

08:00 08 Dec 2022 OVID

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the Ladenburg Thalmann 2022 Healthcare Conference in New York, New York on Thursday, September 29, 2022, at 9:00 a.m. ET.

08:00 08 Dec 2022 OVID

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York, New York on Monday, September 12, 2022, at 12:00 p.m. ET.

07:17 08 Dec 2022 OVID

3 Biotech Stocks Under $10 to Add to Your Buy List

These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on InvestorPlace.

08:00 08 Dec 2022 OVID

Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 12:45 p.m. ET.

08:30 08 Dec 2022 OVID

Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors.

04:30 08 Dec 2022 OVID

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

Dr. Michael Poole to Join the Board of Directors

05:09 08 Dec 2022 OVID

Ovid Therapeutics: Good Entry Point For Investors

There are promising results for OV-935 in patients with Dravet Syndrome, with questionable results in patients with Lennox-Gastaut Syndrome (LGS). Pipeline drug OV-935 shows high revenue potential.

12:02 08 Dec 2022 OVID

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

08:00 08 Dec 2022 OVID

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET.

OVID Financial details

Company Rating
Buy
Market Cap
130.36M
Income
-191.38M
Revenue
-206.72M
Book val./share
2.02
Cash/share
1.96
Dividend
-
Dividend %
-
Employees
44
Optionable
No
Shortable
Yes
Earnings
08 Nov 2022
P/E
-1.85
Forward P/E
-
PEG
0.64
P/S
-0.6
P/B
0.87
P/C
0.92
P/FCF
1.74
Quick Ratio
20.48
Current Ratio
20.87
Debt / Equity
0.11
LT Debt / Equity
0.11
-
-
EPS (TTM)
-0.99
EPS next Y
-
EPS next Q
-
EPS this Y
-100.13%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-19.05%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
50.56%
Inst Trans
1.27%
ROA
-116%
ROE
-120%
ROC
-0.44%
Gross Margin
-101%
Oper. Margin
34%
Profit Margin
93%
Payout
-
Shs Outstand
70.47M
Shs Float
37.55M
-
-
-
-
Target Price
-
52W Range
1.405-3.6
52W High
-40%
52W Low
+80%
RSI
53
Rel Volume
0.4
Avg Volume
104.35K
Volume
41.71K
Perf Week
1.69%
Perf Month
9.09%
Perf Quarter
-2.7%
Perf Half Y
-3.74%
-
-
-
-
Beta
1.14726
-
-
Volatility
0.03%, 0.11%
Prev Close
2.86%
Price
1.8
Change
0%

OVID Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0000.220
Net income per share
-3.35-2.11-1.54-1.390
Operating cash flow per share
-1.63-1.85-1.3-0.882.03K
Free cash flow per share
-1.63-1.86-1.31-0.892.03K
Cash per share
4.51.681.961.233.21
Book value per share
4.311.581.790.753.08
Tangible book value per share
4.311.581.790.753.08
Share holders equity per share
4.311.581.790.753.08
Interest debt per share
00000
Market cap
160.95M78.57M134.52M164.25M157.23M
Enterprise value
73.82M42.08M92.62M92.21M-30.56M
P/E ratio
-2.48-1.51-2.22-2.031.28K
Price to sales ratio
00013.02754.54
POCF ratio
-5.11-1.72-2.63-3.180
PFCF ratio
-5.11-1.71-2.62-3.160
P/B Ratio
1.932.021.923.760.87
PTB ratio
1.932.021.923.760.87
EV to sales
0007.31-146.67
Enterprise value over EBITDA
-1.14-0.8-1.51-1.14-0.13
EV to operating cash flow
-2.35-0.92-1.81-1.790
EV to free cash flow
-2.34-0.92-1.8-1.770
Earnings yield
-0.4-0.66-0.45-0.490
Free cash flow yield
-0.2-0.58-0.38-0.32753.19
Debt to equity
00000
Debt to assets
0.070.190.130.430.08
Net debt to EBITDA
1.340.690.690.89-0.79
Current ratio
14.715.017.583.3912.87
Interest coverage
00000
Income quality
0.490.880.850.64965.63K
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0002.430.18
Research and developement to revenue
0005.030.23
Intangibles to total assets
00000
Capex to operating cash flow
00.0100.010
Capex to revenue
000-0.03-883.03
Capex to depreciation
-0.59-2.48-0.96-1.27-0.78
Stock based compensation to revenue
0000.624.26K
Graham number
18.038.657.874.830.38
ROIC
-0.78-1.36-0.87-1.510.69
Return on tangible assets
-0.72-1.09-0.75-1.070
Graham Net
4.191.331.70.682.96
Working capital
82.57M35.42M69.28M52.78M175.68M
Tangible asset value
00000
Net current asset value
82.57M35.42M68.99M42.55M175.68M
Invested capital
00000
Average receivables
00636.45K141.76K0
Average payables
3.74M4.6M4.35M5.45M6.29M
Average inventory
00000
Days sales outstanding
0004.10
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
000890
Payables turnover
00000
Inventory turnover
00000
ROE
-0.78-1.34-0.86-1.860
Capex per share
0-0.01-0.01-0.01-3.15

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
0-3.050.0200
Net income per share
-0.17-2.18-0.23-0.21-0.17
Operating cash flow per share
-0.161.74-0.29-0.19-0.18
Free cash flow per share
-0.161.74-0.29-0.21-0.18
Cash per share
2.972.762.372.161.96
Book value per share
2.92.642.352.162.02
Tangible book value per share
2.92.642.352.162.01
Share holders equity per share
2.92.642.352.162.02
Interest debt per share
000.230.230.23
Market cap
228.24M218.79M220.89M151.34M129.59M
Enterprise value
26.46M30.99M70.09M94.5M87.58M
P/E ratio
-5.01-0.37-3.43-2.59-2.71
Price to sales ratio
0-1.05152.82011.67K
POCF ratio
-20.991.85-11-11.39-10.22
PFCF ratio
-20.961.85-10.96-10.4-10.21
P/B Ratio
1.161.221.340.990.91
PTB ratio
1.161.221.340.990.91
EV to sales
0-0.1548.4907.89K
Enterprise value over EBITDA
-2.28-0.21-4.38-6.82-7.07
EV to operating cash flow
-2.430.26-3.49-7.11-6.91
EV to free cash flow
-2.430.26-3.48-6.49-6.9
Earnings yield
-0.05-0.68-0.07-0.1-0.09
Free cash flow yield
-0.050.54-0.09-0.1-0.1
Debt to equity
000.10.10.11
Debt to assets
0.050.080.140.140.14
Net debt to EBITDA
17.351.259.434.13.39
Current ratio
20.3712.8716.6316.9420.87
Interest coverage
00000
Income quality
0.96-0.81.250.911.06
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00.146.840687.44
Research and developement to revenue
00.145.420466.88
Intangibles to total assets
00000
Capex to operating cash flow
0000.090
Capex to revenue
00-0.050-1.68
Capex to depreciation
-0.31-0.78-1.03-2.79-0.04
Stock based compensation to revenue
0-0.020.920160.52
Graham number
3.3111.383.483.172.78
ROIC
-0.06-0.15-0.09-0.09-0.08
Return on tangible assets
-0.05-0.76-0.08-0.08-0.07
Graham Net
2.822.542.011.821.63
Working capital
194.99M175.68M159.86M146.87M133.77M
Tangible asset value
0000141.78M
Net current asset value
194.99M175.68M143.99M130.9M117.52M
Invested capital
000.10.10.11
Average receivables
001000K1000K0
Average payables
3.88M5.87M3.44M4.62M2.82M
Average inventory
00000
Days sales outstanding
0062.2700
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
001.4500
Payables turnover
00000
Inventory turnover
00000
ROE
-0.06-0.83-0.1-0.1-0.08
Capex per share
000-0.020

OVID Frequently Asked Questions

What is Ovid Therapeutics Inc. stock symbol ?

Ovid Therapeutics Inc. is a US stock , located in New york city of New york and trading under the symbol OVID

What is Ovid Therapeutics Inc. stock quote today ?

Ovid Therapeutics Inc. stock price is $1.8 today.

Is Ovid Therapeutics Inc. stock public?

Yes, Ovid Therapeutics Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap